QR код

AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors

Abstract Background Non-small cell lung cancer (NSCLC) is a significant global health challenge, with 2% of cases fuelled by RET rearrangements. RET inhibitors (RETi) have revolutionized treatment for these patients, but resistance remains an important clinical challenge limiting therapy effectivene...

Повний опис

Збережено в:
Автори: Daniela Esposito, Claudia Maria Ascione, Stefania Belli, Fabiana Napolitano, Alberto Servetto, Felice Pepe, Umberto Malapelle, Antonino Iaccarino, Giancarlo Troncone, Diletta Barone, Emilio Bria, Roberto Ferrara, Daniele Lorenzini, Giuseppe Lo Russo, Maria Rosa Ghigna, Arianna Marinello, Mihaela Aldea, Benjamin Besse, Luigi Formisano, Roberto Bianco
Формат: Artigo
Мова:Inglês
Опубліковано: BMC 2025-05-01
Серія:Journal of Experimental & Clinical Cancer Research
Предмети:
Non-small cell lung cancer
RET
RET inhibitors
EGFR
Drug resistance
Combination targeted therapy
Онлайн доступ:https://doi.org/10.1186/s13046-025-03392-w
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси